Literature DB >> 6441720

Effect of dipyrone, acetylsalicylic acid and acetaminophen on human neutrophil chemotaxis.

Y Matzner, R Drexler, M Levy.   

Abstract

Dipyrone metabolites 4-methylaminoantipyrine (MAA) and 4-formylaminoantipyrine (FAA) as well as acetylsalicylic acid inhibited neutrophil migration toward zymosan-activated serum. Inhibition was maximal (76.8 +/- 19.0; 79.2 +/- 12.5 and 80.0 +/- 4.4%, respectively, P less than 0.003) when suboptimal concentrations (0.3%) of the chemoattractant were used and could be demonstrated with drug concentrations comparable with plasma concentrations obtained in clinical use. Acetaminophen and other dipyrone metabolites 4-aminoantipyrine (AA) and 4-acetylaminoantipyrine (AAA) lacked chemotactic inhibitory potential. Only MAA and FAA inhibited mildly neutrophil random migration (18.1 +/- 7.8 and 11.2 +/- 3.4%, respectively). We suggest that blocking neutrophil movement plays a role in the anti-inflammatory activity of dipyrone and acetylsalicylic acid, but their mechanism of inhibition remains obscure.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6441720     DOI: 10.1111/j.1365-2362.1984.tb01210.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  4 in total

Review 1.  Pyrazolone derivatives.

Authors:  R N Brogden
Journal:  Drugs       Date:  1986       Impact factor: 9.546

2.  Effect of ambroxol of neutrophil chemotaxis in vitro.

Authors:  R A Stockley; J Shaw; D Burnett
Journal:  Agents Actions       Date:  1988-07

3.  Rose hip inhibits chemotaxis and chemiluminescence of human peripheral blood neutrophils in vitro and reduces certain inflammatory parameters in vivo.

Authors:  A Kharazmi; K Winther
Journal:  Inflammopharmacology       Date:  1999       Impact factor: 4.473

4.  The anti-inflammatory properties of rose-hip.

Authors:  K Winther; E Rein; A Kharazmi
Journal:  Inflammopharmacology       Date:  1999       Impact factor: 4.473

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.